Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol-Myers Squibb news coverage encompasses regulatory developments, clinical trial results, product launches, business transactions, and corporate initiatives. The company's activities across oncology, hematology, immunology, cardiovascular, and neuroscience generate frequent updates that impact stakeholders in the healthcare and investment communities.
Regulatory announcements represent significant news events for Bristol-Myers Squibb, including approvals of new medicines, expanded indications for existing products, and regulatory submissions in various markets. These milestones reflect the progression of the company's pipeline from clinical development through regulatory review to market authorization. Priority review designations, breakthrough therapy designations, and orphan drug designations also generate news coverage as indicators of regulatory progress.
Clinical trial data releases occur at medical conferences, in peer-reviewed publications, and through corporate announcements. Results from pivotal trials evaluating new medicines or expanded uses of approved products receive particular attention from the medical community and investors. The company's extensive clinical trial portfolio across multiple therapeutic areas produces a steady stream of data readouts that inform understanding of product profiles and market potential.
Business development activities including acquisitions, licensing agreements, research collaborations, and strategic partnerships shape Bristol-Myers Squibb's long-term direction. These transactions can bring new assets into the pipeline, provide access to novel technologies, or establish collaborations with academic institutions and biotechnology companies. Divestitures and portfolio prioritization decisions also generate news coverage.
Commercial performance updates occur through periodic financial reporting and corporate presentations. These updates provide insight into product uptake, market penetration, competitive dynamics, and the impact of healthcare policy changes on business results. Manufacturing capacity expansions, supply chain developments, and commercial launches in new geographic markets represent additional categories of business news.
Corporate initiatives related to sustainability, patient access, health equity, research funding, and community engagement reflect broader aspects of Bristol-Myers Squibb's operations beyond drug development and commercialization. Leadership changes, organizational restructuring, and strategic priority shifts also contribute to news flow.
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) announced the expiration of the waiting period under the HSR Act, receiving merger control clearance from the Federal Cartel Office of Germany. The acquisition offer to buy all outstanding shares of Turning Point for $76.00 per share, totaling approximately $4.1 billion, is set to close on August 17, 2022. Approximately 41.9 million shares, or 84% of Turning Point's outstanding shares, were validly tendered as of the Offer's expiration on August 15, 2022.
Bristol Myers Squibb (NYSE: BMY) and 2seventy bio (NASDAQ: TSVT) announced positive topline results from the Phase 3 KarMMa-3 study, evaluating Abecma (idecabtagene vicleucel) in relapsed and refractory multiple myeloma. The trial met its primary endpoint, showing statistically significant improvement in progression-free survival versus standard treatments. Key secondary endpoints, including overall response rate, also showed improvement. No new safety signals were reported, confirming Abecma's well-established safety profile.
Bristol Myers Squibb (NYSE: BMY) announced a virtual Investor Event on August 28, 2022, at 7:00 p.m. CET / 1:00 p.m. ET. The event will discuss data from the AXIOMATIC-SSP Phase 2 trial of milvexian for secondary stroke prevention presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain. Executives will offer insights on the data and answer investor questions. Interested parties can access the live webcast on the company's investor relations website, with archived content available later the same day.
Bristol Myers Squibb (NYSE: BMY) announced that Part A of the Phase 3 CheckMate -914 trial did not meet its primary endpoint of disease-free survival for the combination therapy of Opdivo and Yervoy in patients with localized renal cell carcinoma after kidney surgery. Despite previous successes in treating other stages of RCC, this trial's outcome is disappointing. The company remains committed to research in this area and will evaluate the data for further insights.
Bristol Myers Squibb (NYSE:BMY) reported Q2 2022 revenues of $11.9 billion, a 2% year-over-year increase, or 5% when adjusted for foreign exchange. GAAP EPS rose 40% to $0.66, while non-GAAP EPS reached $1.93, mainly impacted by ($0.14) per share from Acquired IPRD charges. 11% revenue growth was noted in in-line products. The company reaffirmed non-GAAP EPS guidance for 2022 while adjusting GAAP EPS guidance. Additionally, they announced plans to acquire Turning Point Therapeutics (NASDAQ:TPTX) for $4.1 billion, expanding their precision oncology portfolio.
Bristol Myers Squibb (NYSE: BMY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the fixed-dose combination of nivolumab and relatlimab for treating advanced melanoma. This treatment targets adults and adolescents with a tumor cell PD-L1 expression < 1%. The recommendation is based on the Phase 2/3 RELATIVITY-047 trial results, which demonstrated over twofold increased median progression-free survival compared to nivolumab monotherapy. This would mark the first LAG-3 antibody combination approved in Europe.
Bristol Myers Squibb (BMY) has announced a three-year exclusive collaboration with Jack and Jill of America, Inc. aimed at enhancing diversity within the biopharma sector. This partnership will launch at the "Power of a Dream" National Convention in Orlando, Florida, from July 26-31. The initiative seeks to inspire more Black and African American youth to enter the biopharma industry, emphasizing health equity and better outcomes for marginalized communities. This aligns with BMY's commitment to fostering a sustainable pipeline of diverse talent from Historically Black Colleges and Universities.
Bristol Myers Squibb (NYSE:BMY) has announced an extension of its offer to acquire Turning Point Therapeutics (NASDAQ:TPTX) until August 15, 2022. The offer price remains at $76.00 per share in cash, previously set to expire on July 18, 2022. As of the last update, 34,447,733 shares, approximately 69.0% of Turning Point's outstanding shares, were tendered. The acquisition is anticipated to close in the third quarter of 2022, subject to various regulatory conditions.
Bristol Myers Squibb (NYSE: BMY) has announced the FDA's approval of Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy specifically for adult patients with large B-cell lymphoma (LBCL). This approval is rooted in pivotal trial data demonstrating a median event-free survival of 10.1 months for Breyanzi versus 2.3 months for standard care, highlighting its significant efficacy. Notably, Breyanzi now features the broadest patient eligibility criteria among CAR T therapies for relapsed or refractory LBCL, marking a milestone in cancer treatment innovation.
Bristol Myers Squibb (NYSE:BMY) announced new findings from the Zeposia (ozanimod) Phase 3 DAYBREAK trial, demonstrating cognitive benefits for patients with relapsing multiple sclerosis (MS). In patients with high thalamic volume, 45.5% showed improvement in cognitive function at Month 48. Zeposia was well tolerated, with over 80% of participants remaining on treatment through 48 months. These results highlight the importance of early treatment in preserving cognitive function, which will be presented at the European Academy of Neurology Congress in Vienna, Austria.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
